Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer

Clinical impact of K-ras mutation analysis in EUS-guided FNA specimens from pancreatic masses

(2012) Takeshi Ogura et al.   GASTROINTESTINAL ENDOSCOPY

KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy

(2011) F. Kullmann et al.   ONCOLOGY

K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer

(2010) H. Chen et al.   EJSO

CA 19-9 as a Predictor for Response and Survival in Advanced Pancreatic Cancer Patients Treated With Chemoradiotherapy

(2008) Woong Sub Koom et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pancreatic Carcinogenesis

(2008) Jan-Bart M. Koorstra et al.   PANCREATOLOGY

Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine

(2006) Akira Sawaki et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY